PMID- 32705907
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220531
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 33
IP  - 2
DP  - 2022 Mar
TI  - Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 
      44-week real-life experience.
PG  - 1074-1078
LID - 10.1080/09546634.2020.1800577 [doi]
AB  - OBJECTIVES: We aimed to evaluate the effectiveness, safety and tolerability of 
      guselkumab in a real-life setting. METHODS: A prospective, observational, 
      single-center, real-life study including patients under guselkumab treatment from 
      October 2018 to January 2020 was conducted. RESULTS: Twenty-three patients with 
      moderate-to-severe psoriasis were enrolled and twenty-two continued the treatment 
      until week 44. One patient discontinued for increase in liver enzymes. At 
      baseline, mean PASI score was 15.1 +/- 6.1, which reduced up to 3.2 +/- 1.9 at week 
      12 (p < .001) and 0.8 +/- 0.7 at week 44 (p < .001). BSA reduced from 36.4 +/- 13.6 
      at baseline, to 8.3 +/- 7.4 at week 12 (p < .001), up to 2.2 +/- 1.4 at week 44 
      (p < .001). A total of 4 patients (17.4%) experienced mild blood tests 
      alterations and 6 subjects (26%) experienced potential adverse events (AEs). No 
      AEs required guselkumab discontinuation. No cases of serious AEs, injection site 
      reaction, candida, malignancy, cardiovascular events were reported. CONCLUSIONS: 
      Patients under guselkumab therapy reach an optimal clinical response, even in a 
      real-life and long-term setting.
FAU - Megna, Matteo
AU  - Megna M
AUID- ORCID: 0000-0003-1803-2046
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Fabbrocini, Gabriella
AU  - Fabbrocini G
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Cinelli, Eleonora
AU  - Cinelli E
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Camela, Elisa
AU  - Camela E
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Ruggiero, Angelo
AU  - Ruggiero A
AUID- ORCID: 0000-0002-4658-7391
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200804
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 089658A12D (guselkumab)
SB  - IM
MH  - *Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Humans
MH  - Prospective Studies
MH  - *Psoriasis/chemically induced/drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Guselkumab
OT  - anti-IL-23
OT  - biologics
OT  - psoriasis
OT  - real-life
EDAT- 2020/07/25 06:00
MHDA- 2022/04/08 06:00
CRDT- 2020/07/25 06:00
PHST- 2020/07/25 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2020/07/25 06:00 [entrez]
AID - 10.1080/09546634.2020.1800577 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2022 Mar;33(2):1074-1078. doi: 10.1080/09546634.2020.1800577. 
      Epub 2020 Aug 4.